NF-κB

<p>IMD-vanillin is a novel compound characterized as an imidazoquinolinone-derived dimer with NF-κB immunomodulatory properties.</p>

<p>Bay 65-1942 R form is the less active R-form of Bay 65-1942. Bay 65-1942 is a selective and ATP-competitive IKKβ inhibitor.</p>

<p>IMD-biphenylC: New, dual-action imidazoquinolinone dimer; inhibits tumor growth, low inflammation/toxicity.</p>

<p>IRAK4-IN-28 (compound 42), an orally-active IRAK4 inhibitor (IC50=8.9 nM), exhibits strong binding affinity with a Kd of 0.58 nM for the target enzyme.</p>

<p>ACHP Hydrochloride (IKK-2 Inhibitor VIII) is a highly potent and selective IKK-β inhibitor with an IC50 of 8.5 nM.</p>

<p>IR-Crizotinib is a conjugate of the near-infrared dye IR-786 and Crizotinib, an NF-κB-inducing kinase (NIK) inhibitor, with an IC50 of 3.381 μM for intracranial</p>

<p>Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.</p>

<p>Glabrescone C exhibits strong anti-inflammatory properties through direct binding to IKKα/β.</p>

Dimethoxycurcumin is a stable curcumin analog causing epigenetic shifts in leukemia cells, affecting gene expression.

<p>RIP1 Kinase Inhibitor 4 (Compound 3) is an effective inhibitor of RIP1K, exhibiting an EC50 of ≤ 1000 nM [1].</p>

<p>IKK-IN-4 is a potent and selective inhibitor of IkappaB kinase 2 with IC 50 values of 45 and 650 nM against IKKβ and IKKα, respectively [1].</p>

<p>IKK-IN-1 is an inhibitor of IKK.</p>

<p>PK68 selectively inhibits RIPK1 (IC50=90nM), potentially useful in inflammation and cancer metastasis studies.</p>

<p>LTβR-IN-1 is a potent and selective lymphin β receptor (LTβR) inhibitor.</p>

<p>RIPK1-IN-4 is a potent and selective type II kinase receptor interacting protein 1 (RIP1) kinase inhibitor and binds to a DLG-out inactive form of RIP1 (IC50s</p>

<p>Oditrasertib, a RIPK1 inhibitor characterized by an IC50 value below 100 nM, is employed in inflammation research.</p>

<p>Supercinnamaldehyde is a potent activator of transient receptor potential ankyrin 1 (TRPA1), exhibiting an EC50 of 0.8 μM, and induces activation of TRPA1 ion</p>

<p>Ocadusertib is an effective inhibitor of the serine/threonine kinase receptor-interacting protein kinase 1 (RIPK1).</p>

<p>DBMB is a spleen tyrosine kinase (Syk) inhibitor that significantly suppresses Syk enzyme activity. It possesses anti-inflammatory properties by inhibiting NF-κB signaling, thereby reducing the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases.</p>

<p>NLRP3-IN-78 (compound 21) is an NLRP3 inhibitor with a 46.72% inhibition rate of GSDMD-induced pyroptosis at 5 μM. It binds to the NLRP3 protein and prevents GSDMD-NT oligomerization. Additionally, NLRP3-IN-78 inhibits GSDMD cleavage and upstream NF-κB signaling, demonstrating anti-inflammatory activity.</p>

<p>TLR4/NF-κB/MAPK-IN-1 is a novel antineuroinflammatory agent that functions by inhibiting the TLR4/NF-κB/MAPK pathways.</p>

<p>OxLig-1 (7-Ketocholesteryl-9-carboxynonanoate) constitutes a lipid component of oxidized low-density lipoprotein (oxLDL) and serves as a critical ligand for β-glycoprotein I (β(2)-GPI). It induces nuclear translocation by activating the NF-κB pathway. Additionally, oxLig-1 is utilized in the study of atherosclerosis (AS).</p>

<p>TNFα Activity Modulator 3 (example 6) is a molecule that regulates TNF activity by inhibiting TNFα-induced NF-κB activation, making it applicable for related research.</p>

<p>TBK1/IKKε-IN-1 is a dual inhibitor of TBK1 and IKKε (IC50s of &lt;100 nM).</p>

<p>NIK-IN-2 (compound 1) is an effective inhibitor of NF-κB inducing kinase (NIK), exhibiting a pIC50 of 7.4. It plays a crucial role in cancer research.</p>

<p>K-14585 blocks PAR(2), reduces NFkappaB activity, and IL-8 response, but alone can boost IL-8.</p>

<p>SBI-0640726, an eIF4G1 inhibitor, exhibits antiproliferative activity against melanoma. It disrupts the eIF4F translation initiation complex by inhibiting the AKT and NF-kB signaling pathways. Additionally, SBI-0640726 inhibits the growth of melanoma with NRAS and BRAF mutations in vitro.</p>

<p>AS2690168 freebase is an orally active inhibitor of RANKL signaling, capable of suppressing RANKL-induced osteoclastogenesis in RAW264 cells. AS2690168 is applicable in research related to pathological bone resorption.</p>

<p>Anti-inflammatory agent 6 blocks IKKα/β, IκBα, and NF-κB p65 phosphorylation, key to controlling inflammation.</p>

<p>NF-κB-IN-6 (Compound 3d) is an anti-inflammatory agent that works by reducing the protein expression of iNOS and COX-2 by suppressing the NF-κB signaling</p>

<p>4-Octylphenol is an endocrine disruptor with gender-specific effects on male germ cells, significantly reducing the mitotic index and the number of spermatogonia. It also causes inflammatory damage in the gills of carp by activating the complement system through the C3a/C3a receptor (C3a/C3aR) axis and C5a/C5a receptor 1 (C5a/C5aR1) axis. Furthermore, 4-Octylphenol induces immune suppression by disrupting the balance between helper T (Th) cells 1/Th2 and regulatory T (Treg)/Th17 cells, and triggers inflammatory damage through the Toll-like receptor 7 (Toll-like Receptor (TLR))/inhibitor κBα/nuclear factor κB (TLR7/IκBα/NF-κB) pathway.</p>

<p>MAY0132 is a potent and selective EPAC2 inhibitor with an IC50 of 0.4 μM. It significantly inhibits the replication of HMPV, AdV, and RSV, reduces cytokine/chemokine production induced by viral infections, and suppresses NF-κB activation. MAY0132 exhibits antiviral activity and can be used in respiratory virus infection research.</p>

<p>AS2690168 hydrochloride is an orally active inhibitor of RANKL signaling that can suppress RANKL-induced osteoclastogenesis in RAW264 cells. AS2690168 is applicable in research related to pathological bone resorption.</p>

GTCpFE, a compound synthesized from Dimethyl fumarate (DMF) and Aspirin (ASA), inhibits IKKα/β in the NF-κB pathway, exhibiting anti-inflammatory activity by preventing p65 from entering the nucleus. It selectively inhibits cancer stem cell (CSC) activity by reducing the growth of mammospheres and the expression of the CD44+CD24- immune phenotype. Furthermore, GTCpFE targets breast cancer stem cells, crucial in aggressive cancer phenotypes that depend on NFκB and PGE2.

<p>RIPK1-IN-19 is a selective and potent RIPK1 inhibitor that protects against cell necrosis in the tnf α-induced SIRS model and IMQ-induced psoriasis model.</p>

<p>Zharp1-211 is a RIPK3 inhibitor，reduces JAK/ stat1-mediated chemokines and MHC class II molecules in IECs, (GVHD) for gastrointestinal inflammation.</p>

<p>HOIPIN-8 sodium is a LUBAC inhibitor for the study of inflammatory and immune diseases.</p>

<p>Antiproliferative agent-22 is an anticancer compound that shows antiproliferative activity on MCF-7, MDA-MB-231 and MDA-MB-468 cells.</p>

<p>UBS109, a curcumin analog, is a DNA demethylating agent in pancreatic cancer that promotes osteoblast differentiation and mineralization.</p>

<p>Tripeptide-41 (CG-Lipoxyn) is a bioactive peptide known for its ability to reduce fat accumulation.</p>

<p>2,3-Bis(3-indolylmethyl)indole exhibits a concentration-dependent inhibition of RANKL-induced osteoclastogenesis, actin ring formation, and bone resorption.</p>

<p>ALPK1-IN-2 is a potent inhibitor of ALPK1 (α-kinase 1) (IC50: 95 nM). ALPK1-IN-2 inhibits NF-κB (IC50: 1.31 μM).</p>

<p>ALPK1-IN-1 (A001) strongly inhibits ALPK1, key for innate immunity &amp; NF-κB signaling via TIFA/TRAF.</p>

<p>ALPK1-IN-3,serves as an ALPK1 inhibitor that dampens proinflammatory gene expression in the kidney and enhances survival in animal models of sepsis-induced</p>